The rapid growth of a company often comes with a warning label: a sky-high valuation that can amplify losses if the expansion story falters. For investors seeking a more balanced path, the "Affordable Growth" strategy provides a disciplined framework. This method uses ChartMill’s fundamental ratings to target stocks that demonstrate strong growth while avoiding excessive overvaluation. The screen specifically looks for securities with a Growth rating above 7, a Valuation rating above 5, and decent scores for both Profitability and Health—typically a 5 or higher. The logic is straightforward: sustainable growth is more attractive when a company isn't paying an extreme price for it, and solid financial health ensures the business has the operational strength to support its expansion.
A recent pass through this screen flagged TransMedics Group (NASDAQ:TMDX) as an interesting candidate for affordable growth investors. The company, which specializes in its Organ Care System (OCS) for warm perfusion and transport of donor organs, has carved out a unique and growing niche in the transplant space.
Growth Profile: Impressive Momentum
The core of the affordable growth thesis is that the company delivers on its expansion promises. TransMedics does not disappoint here. According to its fundamental report, the company earns a standout ChartMill Growth rating of 7 out of 10.
Looking under the hood, the numbers show a company in a strong growth phase:
- Earnings Per Share (EPS): The EPS has grown by an impressive 77.21% over the past year.
- Revenue: Revenue surged by 30.24% in the last year, with a multi-year annualized growth rate of 88.21%.
- Forward Expectations: Analysts expect this momentum to continue, with EPS forecast to grow at an average of 23.02% per year over the next several years.
This sustained performance is exactly what the affordable growth strategy is designed to capture. It suggests that the company's core business of organ procurement and perfusion is not just a one-time event but is building a scalable, recurring model.
Valuation: Not Overpaying for the Story
Where the affordable growth screen differs from a pure "growth at any cost" approach is in valuation. Here, TransMedics presents a nuanced but favorable picture. Its Valuation score is a 5 out of 10, indicating it is not cheap in an absolute sense, but it is reasonably priced relative to its growth trajectory and industry peers.
Key valuation metrics reveal this balance:
- Price/Earnings (P/E) Ratio: At 28.40, the P/E is above the average S&P 500 ratio of 27.04. However, within its own industry, this actually looks quite reasonable; TransMedics is cheaper than 74.33% of its Health Care Equipment & Supplies peers.
- Forward P/E: Looking ahead, the forward P/E drops to 18.64, which is actually lower than the S&P 500’s forward average. This shows that current earnings are valued more attractively when projected growth is factored in.
- EV/EBITDA and P/FCF: The stock is also cheaper than roughly 73% and 94% of its industry peers on Enterprise Value-to-EBITDA and Price-to-Free Cash Flow multiples, respectively.
This pricing dynamic is important. It suggests that while the market appreciates TransMedics’ story, it hasn’t pushed the stock into bubble territory. The growth is being rewarded, but not irrationally so—a core tenet of the affordable growth strategy.
Profitability and Health: The Foundation of Sustainability
Growth is hollow if the company isn't profitable or is drowning in debt. This is where the screen’s secondary filters provide a necessary check. TransMedics scores a 6 out of 10 in both Profitability and Health, which are solid, if not spectacular, marks.
Profitability Highlights:
- Return on Equity (ROE): An excellent 34.80%, outperforming 97.33% of industry peers.
- Return on Assets (ROA): A healthy 11.98%, beating 93.05% of competitors.
- Profit Margin: A strong 27.04%, again in the top tier of the industry.
Health Metrics:
- Liquidity: The company has a current ratio of 6.74 and a quick ratio of 6.19, indicating ample short-term financial flexibility.
- Solvency: The Altman-Z score of 2.35 suggests only limited bankruptcy risk, and the Debt-to-FCF ratio of 5.66 is manageable.
The sole concern is the Debt-to-Equity ratio of 1.70, which is on the higher side and suggests the company relies on debt financing. However, this is partially offset by strong operational cash flow and the strong liquidity ratios. For the affordable growth investor, this is a yellow flag, not a red one—it warrants monitoring but doesn't break the thesis.
An Affordable Growth Candidate in a Niche Market
TransMedics presents a solid case for the "Affordable Growth" label. It combines high double-digit revenue and earnings growth with valuations that are reasonable, especially when compared to its industry. The company’s solid profitability and manageable financial health provide the operational backbone needed to sustain its expansion. While it carries some debt, the overall profile is one of a growth company that hasn’t been bid up to unreasonable levels.
For investors looking to explore more stocks that fit this disciplined approach—combining strong growth with reasonable valuations and sound fundamentals—the full selection can be reviewed via the Affordable Growth Stock Screener. Use it to find other potential opportunities where quality growth meets fair pricing.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a financial advisor before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
TransMedics Group (NASDAQ:TMDX) Screens as an Affordable Growth Stock with Strong Momentum
The rapid growth of a company often comes with a warning label: a sky-high valuation that can amplify losses if the expansion story falters. For investors seeking a more balanced path, the "Affordable Growth" strategy provides a disciplined framework. This method uses ChartMill’s fundamental ratings to target stocks that demonstrate strong growth while avoiding excessive overvaluation. The screen specifically looks for securities with a Growth rating above 7, a Valuation rating above 5, and decent scores for both Profitability and Health—typically a 5 or higher. The logic is straightforward: sustainable growth is more attractive when a company isn't paying an extreme price for it, and solid financial health ensures the business has the operational strength to support its expansion.
A recent pass through this screen flagged TransMedics Group (NASDAQ:TMDX) as an interesting candidate for affordable growth investors. The company, which specializes in its Organ Care System (OCS) for warm perfusion and transport of donor organs, has carved out a unique and growing niche in the transplant space.
Growth Profile: Impressive Momentum
The core of the affordable growth thesis is that the company delivers on its expansion promises. TransMedics does not disappoint here. According to its fundamental report, the company earns a standout ChartMill Growth rating of 7 out of 10.
Looking under the hood, the numbers show a company in a strong growth phase:
This sustained performance is exactly what the affordable growth strategy is designed to capture. It suggests that the company's core business of organ procurement and perfusion is not just a one-time event but is building a scalable, recurring model.
Valuation: Not Overpaying for the Story
Where the affordable growth screen differs from a pure "growth at any cost" approach is in valuation. Here, TransMedics presents a nuanced but favorable picture. Its Valuation score is a 5 out of 10, indicating it is not cheap in an absolute sense, but it is reasonably priced relative to its growth trajectory and industry peers.
Key valuation metrics reveal this balance:
This pricing dynamic is important. It suggests that while the market appreciates TransMedics’ story, it hasn’t pushed the stock into bubble territory. The growth is being rewarded, but not irrationally so—a core tenet of the affordable growth strategy.
Profitability and Health: The Foundation of Sustainability
Growth is hollow if the company isn't profitable or is drowning in debt. This is where the screen’s secondary filters provide a necessary check. TransMedics scores a 6 out of 10 in both Profitability and Health, which are solid, if not spectacular, marks.
Profitability Highlights:
Health Metrics:
The sole concern is the Debt-to-Equity ratio of 1.70, which is on the higher side and suggests the company relies on debt financing. However, this is partially offset by strong operational cash flow and the strong liquidity ratios. For the affordable growth investor, this is a yellow flag, not a red one—it warrants monitoring but doesn't break the thesis.
An Affordable Growth Candidate in a Niche Market
TransMedics presents a solid case for the "Affordable Growth" label. It combines high double-digit revenue and earnings growth with valuations that are reasonable, especially when compared to its industry. The company’s solid profitability and manageable financial health provide the operational backbone needed to sustain its expansion. While it carries some debt, the overall profile is one of a growth company that hasn’t been bid up to unreasonable levels.
For investors looking to explore more stocks that fit this disciplined approach—combining strong growth with reasonable valuations and sound fundamentals—the full selection can be reviewed via the Affordable Growth Stock Screener. Use it to find other potential opportunities where quality growth meets fair pricing.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a financial advisor before making any investment decisions.
Read full article here »